CARA Therapeutics, Inc. (CARA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about CARA Therapeutics, Inc. (CARA)
Go deeper and ask any question about CARA
Company Performance
Current Price
as of Sep 13, 2024$0.26
P/E Ratio
N/A
Market Cap
$14.4M
Description
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Metrics
Overview
- HQStamford, CT
- SectorHealth Technology
- IndustryBiotechnology
- TickerCARA
- Price$0.2625-2.85%
Trading Information
- Market Cap$14.40M
- Float83.43%
- Average Daily Volume (1m)400,386
- Average Daily Volume (3m)843,957
- EPS-$2.04
Company
- Revenue$11.00M
- Rev Growth (1yr)-85.71%
- Net Income-$20.02M
- Gross Margin92.23%
- EBITDA Margin-1,628.36%
- EBITDA-$16.14M
- EV$4.66M
- EV/Revenue0.42
- P/EN/A
- P/S1.31
Documents
SEC Filings
Factset Street Account